Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276229 | 0.84 | HTR6 (0.41) | HTR6CYP3A4CYP2D6DRD2 | |
| SCHEMBL2674411 | 0.80 | PIK3CD (0.48) | PIK3CDHTR6CYP3A4PIK3CACYP2D6 | |
| SCHEMBL2674658 | 0.76 | PIK3CA (0.50) | PIK3CDPIK3CA | |
| SCHEMBL2112899 | 0.69 | HTR6 (0.38) | HTR6CYP3A4CYP2D6DRD2 | |
| SCHEMBL2673516 | 0.69 | PIK3CD (0.67) | PIK3CDCYP3A4PIK3CA | |
| SCHEMBL10276767 | 0.68 | PIK3CD (0.45) | PIK3CDCYP3A4PIK3CA | |
| SCHEMBL2674654 | 0.64 | PIK3CD (0.45) | PIK3CDCYP3A4PIK3CA | |
| SCHEMBL4546716 | 0.64 | PIK3CD (0.68) | PIK3CDCYP3A4PIK3CAKCNH2 | |
| SCHEMBL2672969 | 0.64 | HTR6 (0.41) | PIK3CDHTR6CYP3A4PIK3CACYP2D6 | |
| SCHEMBL3780081 | 0.63 | PIK3CA (0.46) | PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885HTR6 4267/4885CYP3A4 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.